SVE
ENG
December 9, 2020 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Tuesday 12 January, 2021 at 10.00 p.m. (CET) through advance voting. Attendance at the meeting is only possible via postal ballot.
Phase III plan laid out
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES.
November 25, 2020 – InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) (Nasdaq First North Growth Market: INDEX) intends to carry out a fully guaranteed rights issue of approximately SEK 500 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Company’s Board of Directors intends to propose that an extraordinary general meeting to be held in January 2021 (the “EGM”) would authorize the Board of Directors to resolve on the Rights Issue and the terms thereof. The net proceeds from the contemplated Rights Issue are mainly intended to be used to fund the important initial induction study in a sequential phase III program in moderate to severe left-sided ulcerative colitis for the Company’s lead drug candidate, cobitolimod. A notice to the EGM will be announced through a separate press release at a later date.
Focus on phase III preparations
FDA and EMA endorse the advancement of cobitolimod into phase III studies
April 20, 2020 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm, Sweden. The following resolutions, amongst others, were passed at the general meeting:
April 16, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III development of the company’s TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis. The company is continuing its phase III preparations, including efforts to secure financing.
March 30, 2020 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2019. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/category/annual-reports/.
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail.
March 19, 2020 – The shareholders in InDex Pharmaceuticals Holding AB, reg. no. 559067-6820 (the “Company”), are hereby given notice to attend the annual general meeting at 5 p.m. on Monday 20 April 2020 at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 4.30 p.m.
Cobitolimod’s outstanding combination of efficacy and safety confirmed in in-depth analysis
February 19, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that the highest dose tested, which met the primary endpoint of the study, demonstrates an outstanding combination of efficacy and safety.
